Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Download

Total Articles

10
(from Reference Citation Analysis)

Article PDFs (1)

Cited by > 0 (5)

Searched Name

Gabriele Piesco

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Type

Show more Refine

Article Statistics

Refine

MESH Headings

Show more Refine

First Author

Show more Refine

First Author Affiliations

Show more Refine

Authors

Show more Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Countries/Regions

Show more Refine

Affiliations

Show more Refine

Corresponding Author Affiliations

Show more Refine

Category

Show more Refine

Number

Citation Analysis

Falcone R, Verkhovskaia S, Di Pietro FR, Poti G, Samela T, Carbone ML, Morelli MF, Zappalà AR, di Rocco ZC, Morese R, Piesco G, Marchetti P, Failla CM, De Galitiis F. Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center. Curr Oncol 2024;31:588-597. [PMID: 38275835 PMCID: PMC10814710 DOI: 10.3390/curroncol31010042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2023] [Revised: 01/13/2024] [Accepted: 01/19/2024] [Indexed: 01/27/2024] Open

Abstract

(1) Background: Mucosal melanoma (MM) is a rare tumor, accounting for about 1% of all diagnosed melanomas. The etiology and pathogenesis of this tumor are unknown. It is characterized by an aggressive phenotype with poor prognosis and a low response rate to approved treatments. (2) Methods: We retrospectively analyzed the clinical features, treatments and outcomes of patients diagnosed with MM from different sub-sites (head and neck, gynecological and gastro-intestinal region) between 2013 and 2023 at our Institute. Survival times were estimated with the Kaplan-Meier method. Multivariate Cox regression was used to test the independence of significant factors in univariate analysis. (3) Results: Twenty-five patients were included in this study; the disease was equally distributed among females and males. The median age at diagnosis was 74 years old. The majority had MM originating from the head and neck (56%), particularly from the nasal cavity. BRAF V600 mutations were detected in 16% of the study population, limited to gastro-intestinal and gynecological MM. At diagnosis, at least half the patients (52%) had the disease located also at distant sites. The median overall survival (OS) in the whole study population was 22 months, with a longer OS for patients diagnosed at an early stage (38 months, p < 0.001). Longer OSs were reported for head and neck MM compared to other anatomic regions (0.06). Surgery of the primary tumor and radiotherapy were performed in 64% and 36% of the study population, respectively. Radiotherapy was performed only in head and neck MM. At multivariate analysis, the single factor that showed a reduced hazard ratio for death was radiotherapy. (4) Conclusions: The overall survival of MM from different sub-sites treated at our Italian Institution was 22 months, with better outcomes for early-stage disease and head and neck MM. Performing radiotherapy may have a protective effect on OS for head and neck MM. New treatment strategies are urgently needed to improve the outcome in this disease.

Collapse

Affiliation(s)

Rosa Falcone Department of Oncology, IDI-IRCCS, 00167 Rome, Italy; (S.V.); (F.R.D.P.); (G.P.); (T.S.); (M.F.M.); (A.R.Z.); (Z.C.d.R.); (R.M.); (G.P.); (P.M.); (F.D.G.)
Sofia Verkhovskaia Department of Oncology, IDI-IRCCS, 00167 Rome, Italy; (S.V.); (F.R.D.P.); (G.P.); (T.S.); (M.F.M.); (A.R.Z.); (Z.C.d.R.); (R.M.); (G.P.); (P.M.); (F.D.G.)
Francesca Romana Di Pietro Department of Oncology, IDI-IRCCS, 00167 Rome, Italy; (S.V.); (F.R.D.P.); (G.P.); (T.S.); (M.F.M.); (A.R.Z.); (Z.C.d.R.); (R.M.); (G.P.); (P.M.); (F.D.G.)
Giulia Poti Department of Oncology, IDI-IRCCS, 00167 Rome, Italy; (S.V.); (F.R.D.P.); (G.P.); (T.S.); (M.F.M.); (A.R.Z.); (Z.C.d.R.); (R.M.); (G.P.); (P.M.); (F.D.G.)
Tonia Samela Department of Oncology, IDI-IRCCS, 00167 Rome, Italy; (S.V.); (F.R.D.P.); (G.P.); (T.S.); (M.F.M.); (A.R.Z.); (Z.C.d.R.); (R.M.); (G.P.); (P.M.); (F.D.G.)
Maria Luigia Carbone Experimental Immunology Laboratory, IDI-IRCCS, 00167 Rome, Italy; (M.L.C.); (C.M.F.)
Maria Francesca Morelli Department of Oncology, IDI-IRCCS, 00167 Rome, Italy; (S.V.); (F.R.D.P.); (G.P.); (T.S.); (M.F.M.); (A.R.Z.); (Z.C.d.R.); (R.M.); (G.P.); (P.M.); (F.D.G.)
Albina Rita Zappalà Department of Oncology, IDI-IRCCS, 00167 Rome, Italy; (S.V.); (F.R.D.P.); (G.P.); (T.S.); (M.F.M.); (A.R.Z.); (Z.C.d.R.); (R.M.); (G.P.); (P.M.); (F.D.G.)
Zorika Christiana di Rocco Department of Oncology, IDI-IRCCS, 00167 Rome, Italy; (S.V.); (F.R.D.P.); (G.P.); (T.S.); (M.F.M.); (A.R.Z.); (Z.C.d.R.); (R.M.); (G.P.); (P.M.); (F.D.G.)
Roberto Morese Department of Oncology, IDI-IRCCS, 00167 Rome, Italy; (S.V.); (F.R.D.P.); (G.P.); (T.S.); (M.F.M.); (A.R.Z.); (Z.C.d.R.); (R.M.); (G.P.); (P.M.); (F.D.G.)
Gabriele Piesco Department of Oncology, IDI-IRCCS, 00167 Rome, Italy; (S.V.); (F.R.D.P.); (G.P.); (T.S.); (M.F.M.); (A.R.Z.); (Z.C.d.R.); (R.M.); (G.P.); (P.M.); (F.D.G.)
Paolo Marchetti Department of Oncology, IDI-IRCCS, 00167 Rome, Italy; (S.V.); (F.R.D.P.); (G.P.); (T.S.); (M.F.M.); (A.R.Z.); (Z.C.d.R.); (R.M.); (G.P.); (P.M.); (F.D.G.)
Cristina Maria Failla Experimental Immunology Laboratory, IDI-IRCCS, 00167 Rome, Italy; (M.L.C.); (C.M.F.)
Federica De Galitiis Department of Oncology, IDI-IRCCS, 00167 Rome, Italy; (S.V.); (F.R.D.P.); (G.P.); (T.S.); (M.F.M.); (A.R.Z.); (Z.C.d.R.); (R.M.); (G.P.); (P.M.); (F.D.G.)

Collapse

Brauner E, Mezi S, Ciolfi A, Ciolfi C, Pucci R, Cassoni A, Battisti A, Piesco G, De Felice F, Pranno N, Armida M, De Angelis F, Romeo U, Capocci M, Tenore G, Tombolini V, Valentini V, Ottolenghi L, Polimeni A, Di Carlo S. A New Medical Record Proposal to the Prognostic Risk Assessment for MRONJ in Oncologic Patients: "Sapienza Head and Neck Unit" Proposal. Int J Environ Res Public Health 2021;18:ijerph18041851. [PMID: 33672876 PMCID: PMC7918934 DOI: 10.3390/ijerph18041851] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/06/2020] [Revised: 01/17/2021] [Accepted: 01/27/2021] [Indexed: 11/30/2022]

Affiliation(s)

Edoardo Brauner Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.)
Silvia Mezi Department of Radiological Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Roma, Italy; (S.M.); (G.P.); (F.D.F.); (V.T.)
Alessandro Ciolfi Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.) Correspondence: ; Tel.: +39-3397737410
Chiara Ciolfi Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.)
Resi Pucci Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.)
Andrea Cassoni Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.)
Andrea Battisti Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.)
Gabriele Piesco Department of Radiological Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Roma, Italy; (S.M.); (G.P.); (F.D.F.); (V.T.)
Francesca De Felice Department of Radiological Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Roma, Italy; (S.M.); (G.P.); (F.D.F.); (V.T.)
Nicola Pranno Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.)
Matteo Armida Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.)
Francesca De Angelis Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.)
Umberto Romeo Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.)
Mauro Capocci Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.)
Gianluca Tenore Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.)
Vincenzo Tombolini Department of Radiological Oncological and Pathological Sciences, Sapienza University of Rome, 00161 Roma, Italy; (S.M.); (G.P.); (F.D.F.); (V.T.)
Valentino Valentini Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.)
Livia Ottolenghi Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.)
Antonella Polimeni Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.)
Stefano Di Carlo Department of Oral and Maxillo-Facial Sciences, Sapienza University of Rome, 00161 Roma, Italy; (E.B.); (C.C.); (R.P.); (A.C.); (A.B.); (N.P.); (M.A.); (F.D.A.); (U.R.); (M.C.); (G.T.); (V.V.); (L.O.); (A.P.); (S.D.C.)

Collapse

Brauner E, Musio D, Mezi S, Ciolfi A, Maghella F, Cassoni A, De Angelis F, Guarino G, Romeo U, Tenore G, Piesco G, De Felice F, Tombolini V, Valentini V, Polimeni A, Di Carlo S. Implant placement in oral squamous cells carcinoma patients treated with chemoradiotherapy: "Sapienza Head and Neck Unit" clinical recommendations. Eur Rev Med Pharmacol Sci 2019;23:9923-9930. [PMID: 31799661 DOI: 10.26355/eurrev_201911_19558] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]

Abstract

OBJECTIVE

To date, the treatment of patients affected by head and neck squamous cell carcinoma (HNSCC) is highly challenging for clinicians. Possible therapies are surgical resection of the tumor mass, radiotherapy, chemotherapy or, more often, a combined treatment that inevitably affects both normal and tumor cells. Consequently, patients' anatomy and functions become reduced or altered. Nowadays the functional restoration is significantly improved thanks to the innovation in prosthetic rehabilitation and in radiotherapy. The current IMRT (Intensity Modulated Radiation Therapy) allows planning adequate treatments evaluating different tissues' involvement and radiation dosage. It is possible to define the most suitable sites for implant insertion, using data provided by dose-volume histogram (DVH). This study aims to illustrate the idea of obtaining a unique CT image by blending radiation-planning CT and Cone Beam CT.

PATIENTS AND METHODS

Five patients among 54 candidates were selected for this study. Selection criteria were: good general health (PS0-1), age between 18 and 72 years, absence of metastatic disease or local recurrence, disease-free interval of at least 18 months. Radiation planning CT scan and maxillo-facial CT Cone Beam of every patient were overlapped and merged. Only one CT for every evaluated patient was obtained in order to plan the most suitable areas for implant placement.

RESULTS

The placement of 10 implants in 5 patients was programmed using the explained method. Patients (all male) were aged between 48 and 72 years old, with a median age of 64.4 years. In every case of this study, a modification of the initial program of implant placement was necessary. The new imaging method we are proposing was able to provide information about radiation isodoses received in the planned osseointegrated implants' positions.

CONCLUSIONS

This new method allows operators to correct their own therapy plans and choices, customizing the treatment plan on the actual condition of the patient. Moreover, it makes all the rehabilitation process safer and can reduce the risk of failure, side effects and inconveniences for the patients.

Collapse

Fabbri M, Botticelli A, Omarini C, Cretella E, Fabi A, Alesini D, Pizzuti L, Piesco G, Vaccaro A, Atzori F, Piacentini F, Moscetti L, Orlandi A, Sini V, Mercanti A, Framarino M, Persano M, Ceccherini R, Ruggeri E. Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open

Fabi A, Giannarelli D, Botticelli A, Scagnoli S, Pellegrino A, Fabbri A, Corsi D, Magri V, Pizzuti L, Paris I, Bruni V, Pace R, Lanzetta G, Stani S, Moscetti L, Marchetti P, Piesco G, Cognetti F, Rossi V. Abstract P4-13-07: SEQUERPLUS: A multicenter real practice observational study investigating the endocrine-based (E) therapies sequential approach in hormonal receptor positive (HR+) HER2 negative (-) metastatic breast cancer (MBC). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-13-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]

Abstract Abstract Background: Despite the sequential E therapy is recognized as the preferred approach for HR+/HER2- MBC, no data from clinical trials support the choice between the different sequential strategies. Methods: In this retrospective study descriptive statistics are reported using the median (Interquartile range, IQR) or frequency. Progression Free Survival (PFS) curves were estimated with the Kaplan-Meier method and compared with the log-rank test. Analysis were performed by SPSS version 21.0 (SPSS Inc., Chicago, IL). Results: From January 2006 to December 2017, 240 patients (pts) with HR+/HER2- MBC receiving at least two consecutive E therapies as first approach were selected from 12 italian cancer centers. The median age at the time of metastasis onset was 63.5 (IQR: 55-72.5) years; 184 (76.7%) pts were in menopausal status; 38 (16%) had de novo stage IV disease and the remaining 202 (84%) had recurrent BC with a median time of 78 months (5-396 months). At the beginning of MBC diagnosis, 148 (62%) pts had a single site of distant disease, 108 (45%) of whom had bone only disease and 45 (18.8%) presented visceral involvement too. The aromatase inhibitor (AI) was chosen as I-line therapy in 146 (60.9%) pts, followed by Fulvestrant (F) in 62 (25.8%) pts; the alternative I-line options were everolimus-exemestane (Eve-Exe), tamoxifene (T), Palbociclib (P)+AI and F+AI in 13 (5.4%), 14 (5.8%), 1 (0.4%) and 4 (1.7%) pts, respectively. The most favourite II-line option resulted F for 111 (46.2%) pts while the Eve-Exe combination was chosen in 70 (29.2%) pts, AI in 30 (12.5%) pts; T, AI+F, P+F and antiprogestincwere administered in 4 (1.7%), 4 (1.7%), 19 (7.9%) and 2 (0.8%) pts, respectively. For I and II-line, the AI followed by F (40%) and F followed by Eve-Exe (18%) were the most common sequential therapeutic approaches; the several alternative options were scanty used (in less than 10%). The median Progression-Free Survival (PFS) from first and second-line E therapies resulted 15.7 (95% CI 13.3-18.1) and 10.3 months (95% CI 8.7-11.9), respectively. Among 194 pts with disease progression after second-line E therapy, 87 (44.8%) received further E therapies with a median PFS 9.4 months (95% CI 7.9-10.9). The remaining 70 (29.2%) pts was treated with palliative chemotherapy. Interestingly, the median Overall Survival (OS) was even longer for pts receiving more lines of E therapies compared to the group with earlier introduction of chemotherapy (204.3 vs 92.8; p=0.007). Finally, in the subgroup analyses a longer PFS benefit was observed in pts with disease recurrence over 12 months from initial diagnosis (38.1 vs 30.3 months p=0.04) and limited sites of disease involvement at the time of MBC diagnosis (37.6 vs 28.3 months, p=0.03) Conclusions: The sequential use in first and second-line setting of E therapies for HR+/HER2- MBC improves median PFS up to 32.3 months. According to real practice experience the optimal sequences could be AIs followed by F and F followed by Eve-Exe. A role for these compounds should be redefined in the light of recently introduction of CDK 4/6 inhibitors in combination with AIs or F for the first or later lines. Citation Format: Fabi A, Giannarelli D, Botticelli A, Scagnoli S, Pellegrino A, Fabbri A, Corsi D, Magri V, Pizzuti L, Paris I, Bruni V, Pace R, Lanzetta G, Stani S, Moscetti L, Marchetti P, Piesco G, Cognetti F, Rossi V. SEQUERPLUS: A multicenter real practice observational study investigating the endocrine-based (E) therapies sequential approach in hormonal receptor positive (HR+) HER2 negative (-) metastatic breast cancer (MBC) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-13-07. Collapse

Affiliation(s)

A Fabi Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
D Giannarelli Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
A Botticelli Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
S Scagnoli Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
A Pellegrino Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
A Fabbri Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
D Corsi Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
V Magri Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
L Pizzuti Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
I Paris Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
V Bruni Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
R Pace Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
G Lanzetta Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
S Stani Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
L Moscetti Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
P Marchetti Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
G Piesco Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
F Cognetti Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy
V Rossi Istituto Regina Elena-IFO, Rome, Italy; S.Andrea Hospital, Rome, Italy; Policlinico Umberto I Hospital, Rome, Italy; San Pietro Hospital, Rome, Italy; Belcolle Hospital, Viterbo, VT, Italy; Fatebenefratelli Hospital, Rome, Italy; Policlinico Universitario A. Gemelli, Rome, Italy; Policlinico Campus Biomedico, Rome, Italy; San Camillo de Lellis, Rieti, Italy; Istituto Neurotraumatologico Italiano, Rome, Italy; Santo Spirito Hospital, Rome, Italy; Azienda Universitaria Ospedaliera of Modena, Modena, Italy; Breast Unit, S.Camillo-Forlanini Hospital, Rome, Italy

Collapse

Caponnetto S, Gelibter A, Mosillo C, Magri V, Scagnoli S, Pomati G, Piesco G, Verkhovskaya S, Pisegna S, Sirgiovanni G, Napoli V, Buscicchio D, Iannantuono G, Marinelli D, Mammone G, Pannunzio S, Nicolo' E, Stefani A, Astorino V, Mancini M, Cortesi E. Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.026] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open

Mezi S, Chiappetta C, Carletti R, Nardini A, Cortesi E, Orsi E, Piesco G, Di Gioia C. Clinical significance of epithelial-to-mesenchymal transition in laryngeal carcinoma: Its role in the different subsites. Head Neck 2017;39:1806-1818. [PMID: 28561907 DOI: 10.1002/hed.24838] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Revised: 03/15/2017] [Accepted: 04/18/2017] [Indexed: 12/17/2022] Open

Caponnetto S, Mancini M, Manai C, Magri V, Iannantuono G, Pellegrino D, Mosillo C, Piesco G, Pomati G, Scagnoli S, Urbano F, Verkhovskaya S, Barchiesi G, Zancla S, Cortesi E. Prolactin as a potential negative predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw378.45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open

Caponnetto S, Mancini M, Scagnoli S, Barchiesi G, Mosillo C, Iannantuono G, Verkhovskaia S, Magri V, Piesco G, Pomati G, Pellegrino D, Urbano F, Zancla S, Manai C, Cortesi E. Prolactin as a possible predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open

Iacovelli R, Modica D, Palazzo A, Trenta P, Piesco G, Cortesi E. Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. Can Urol Assoc J 2015;9:E172-7. [PMID: 26085875 DOI: 10.5489/cuaj.2373] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]